<DOC>
	<DOCNO>NCT00985491</DOCNO>
	<brief_summary>The purpose study determine whether GI Endobarrier Liner safe effective .</brief_summary>
	<brief_title>Study Short Term Weight Loss Candidates Bariatric Surgery</brief_title>
	<detailed_description>Patients obesity significantly great risk develop significant co-morbid complication , associate increase risk all-cause mortality . The GI Endobarrier Liner represent viable alternative short-term weight loss method . It minimally invasive endoscopic procedure , may allow patient recover fast less morbidity mortality . This study investigate safety efficacy GI Endobarrier Liner patient candidate bariatric surgery .</detailed_description>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Age &gt; 18 year &lt; 55 year Male Female BMI &gt; 35 significant comorbidities ( i.e . hypertension , hyperlipidemia , diabetes ) &gt; 40 BMI &lt; 60 ( without comorbid condition ) History failure nonsurgical weight loss method Candidates RouxenY gastric bypass Willing comply trial requirement Signed ICF Postmenopausal woman surgical sterilization follow treatment family plan plan become pregnant course investigation Treatment represent unreasonable risk subject Pregnant intention become pregnant duration trial Unresolved alcohol drug addiction Receiving weight loss medication ( prescription , overthecounter , herbal dietary medication ) Previous gastrointestinal surgery could affect ability place EndoBarrier Liner function implant Active GERD Symptomatic kidney stone prior implant Iron deficiency and/or iron deficiency anemia History Inflammatory bowel disease condition gastrointestinal tract , ulcer Crohn 's disease Symptomatic gallstone prior implant Symptomatic coronary artery disease pulmonary dysfunction Known infection time implant History congenital acquire anomaly gastrointestinal tract atresias stenosis Pancreatitis serious organic condition Requiring prescription anticoagulation therapy Unable discontinue NSAIDs ( nonsteroidal antiinflammatory drug ) implant period Having Family history know diagnosis preexist symptom systemic lupus erythematosus , scleroderma autoimmune connective tissue disorder Participating another ongoing investigational clinical trial Mentally retard emotionally unstable , exhibit psychological characteristic require medication affect appetite ( i.e . tricyclic antidepressant atypical antipsychotic medication ) , opinion Investigator , make subject poor candidate device placement clinical trial Active Helicobacter pylorus ( Note : Subjects may enrol prior history H. Pylori successfully treat ) Having history coagulopathy , upper gastrointestinal bleeding condition esophageal gastric varix , congenital acquire intestinal telangiectasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>obesity</keyword>
</DOC>